Immunicum Doses the First Patient in a New Clinical Phase I/II-Study in Primary Liver Cancer
10/23/2013 9:42:49 AM
Gothenburg, Sweden, 2013-10-23 12:27 CEST (GLOBE NEWSWIRE) -- The first patient in Immunicum’s clinical phase I/II-study in primary liver cancer today received the initial dose of the therapeutic cancer vaccine INTUVAX®. The Company is also finalizing a clinical phase I/II-study in metastatic renal cell carcinoma, initiated in February 2012 and thus far showing promising data.
Help employers find you! Check out all the jobs and post your resume.
comments powered by